Literature DB >> 15868151

Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behçet's disease.

Mustafa Calis1, Filiz Ates, Cevat Yazici, Kader Kose, Mehmet Kirnap, Meltem Demir, Murat Borlu, Cem Evereklioglu.   

Abstract

Behçet's disease (BD) is a systemic vasculitis. Although its clinical characteristics are well defined, the etiology and immune pathogenesis are not clear yet. Neutrophilic vasculitis, which is a consequence of immunological events, is suggested as the underlying pathophysiological mechanism. Adenosine deaminase (ADA) is a non-specific marker of T-lymphocyte activation. A total of 75 patients with BD (45 women and 30 men) and 25 age-matched and gender-matched healthy control volunteers (13 women and 12 men) were included in this study. BD patients were divided into three groups according to their clinical findings: inactive BD patients (group 1, n=25); active BD patients under colchicine treatment (group 2, n=25); and active BD patients without colchicine treatment (group 3, n=25). Plasma ADA (p-ADA) levels of all BD patients and the control group were measured and compared. The relationship between p-ADA levels and disease activity, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels was evaluated and correlated. Patients with BD had significantly higher p-ADA levels (20.6+/-6.3 U/l) than control subjects (12.8+/-1.8 U/l; P<0.001). The p-ADA levels of patients with active BD were significantly (for each, P<0.05) higher than those of inactive BD patients or controls. On the other hand, the difference was not significant (P>0.05) between active patients with or without colchicine use. In addition, there were significantly positive correlations between p-ADA, ESR and CRP levels in patients with BD (for each, P<0.05). However, disease duration or haemoglobin levels were not relevant. ADA level may be a valuable and supportive indicator of disease activity and is not affected by colchicine therapy in BD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868151     DOI: 10.1007/s00296-005-0612-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  25 in total

1.  Increased corneal thickness in active Behçet's disease.

Authors:  C Evereklioglu; H Er
Journal:  Eur J Ophthalmol       Date:  2002 Jan-Feb       Impact factor: 2.597

2.  Audio-vestibular evaluation in patients with Behçet's syndrome.

Authors:  C Evereklioglu; Y Cokkeser; S Doganay; H Er; A Kizilay
Journal:  J Laryngol Otol       Date:  2001-09       Impact factor: 1.469

Review 3.  Current concepts in the etiology and treatment of Behçet disease.

Authors:  Cem Evereklioglu
Journal:  Surv Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 6.048

Review 4.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

5.  Role of gammadelta T lymphocytes in the development of Behçet's disease.

Authors:  N Yamashita; H Kaneoka; S Kaneko; M Takeno; K Oneda; H Koizumi; M Kogure; G Inaba; T Sakane
Journal:  Clin Exp Immunol       Date:  1997-02       Impact factor: 4.330

6.  The evaluation of lipid peroxidation and adenosine deaminase activity in patients with Behçet's disease.

Authors:  K Köse; C Yazici; O Aşşioğlu
Journal:  Clin Biochem       Date:  2001-03       Impact factor: 3.281

7.  Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis.

Authors:  R A Sari; S Taysi; O Yilmaz; N Bakan
Journal:  Clin Exp Rheumatol       Date:  2003 Jan-Feb       Impact factor: 4.473

8.  Serum and pleural adenosine deaminase. Correlation with lymphocytic populations.

Authors:  M F Baganha; A Pêgo; M A Lima; E V Gaspar; A R Cordeiro
Journal:  Chest       Date:  1990-03       Impact factor: 9.410

9.  [Serum adenosine deaminase and angiotensin converting enzyme activity in patients with endogenous uveitis].

Authors:  R Fukami; S Ohba; K Ishida; S Nakamura; M Konno; S Ohno
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1994-03

10.  Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.

Authors:  Cem Evereklioglu; Hamdi Er; Yusuf Türköz; Mustafa Cekmen
Journal:  Mediators Inflamm       Date:  2002-04       Impact factor: 4.711

View more
  11 in total

1.  Synovial fluid adenosine deaminase and high-sensitivity C-reactive protein activity in differentiating monoarthritis.

Authors:  Batool Zamani; Raika Jamali; Hassan Ehteram
Journal:  Rheumatol Int       Date:  2010-08-19       Impact factor: 2.631

2.  A 30-year-old female Behçet's disease patient with recurrent pleural and pericardial effusion and elevated adenosine deaminase levels: case report.

Authors:  Joon Young Choi; Sung-Hwan Kim; Seung-Ki Kwok; Jung Im Jung; Kyo-Young Lee; Tae-Jung Kim; Ji Young Kang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

3.  Assessment of uric acid and lipid peroxidation in serum and urine after hypoxia-ischemia neonatal in rats.

Authors:  V C Pimentel; F V Pinheiro; M Kaefer; R N Moresco; M B Moretto
Journal:  Neurol Sci       Date:  2010-08-21       Impact factor: 3.307

Review 4.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

Review 5.  Behçet syndrome: from pathogenesis to novel therapies.

Authors:  Gianluigi Mazzoccoli; Angela Matarangolo; Rosa Rubino; Michele Inglese; Angelo De Cata
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

6.  Serum adenosine deaminase may predict disease activity in rheumatoid arthritis.

Authors:  Batool Zamani; Raika Jamali; Arsia Jamali
Journal:  Rheumatol Int       Date:  2011-04-03       Impact factor: 2.631

7.  Assessment of adenosine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-alpha therapy.

Authors:  Burak Erer; Gulsen Yilmaz; Fatma Meric Yilmaz; Seyfettin Koklu
Journal:  Rheumatol Int       Date:  2008-10-25       Impact factor: 2.631

8.  Pathophysiology of the Behçet's Disease.

Authors:  Umit Türsen
Journal:  Patholog Res Int       Date:  2011-10-01

9.  Serum Adenosine Deaminase Level is High But Not Related with Disease Activity Parameters in Patients with Rheumatoid Arthritis.

Authors:  Gülseren Demir; Pınar Borman; Figen Ayhan; Tuba Ozgün; Ferda Kaygısız; Gulsen Yilmez
Journal:  Open Rheumatol J       Date:  2014-09-12

10.  Sensitivity and specificity of adenosine deaminase in diagnosis of juvenile idiopathic arthritis.

Authors:  Mina Doudkani-Fard; Vahid Ziaee; Mohamad-Hassan Moradinejad; Mojtaba Sedaghat; Mohammad-Taghi Haghi-Ashtiani; Zahra Ahmadinejad
Journal:  Med J Islam Repub Iran       Date:  2014-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.